지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.2
- 수록면
- 268 - 275 (8page)
이용수
초록· 키워드
오류제보하기
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease globally, and its prevalence is rapidly increasing. Nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD, is characterized by hepatocellular injury, inflammation, and fibrosis. Patients with NASH or severe fibrosis should be treated according to international NAFLD guidelines. Currently, regulatory agencies have not approved any pharmaceutical treatment for NAFLD. Vitamin E and pioglitazone are efficacious for NASH resolution; however, their benefits must be weighed against the reported risks. In a phase 2 trial, a glucagon-like peptide-1 agonist commonly used for diabetes and obesity was found to improve liver histology in patients with NASH. Furthermore, therapeutic agents targeting NASH pathogenesis, including bile acid signaling, insulin resistance, and lipid metabolism, are in various phases of clinical development. In this article, we review the benefits and drawbacks of current pharmacotherapy and the efficacy of upcoming treatments for NASH.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
비알코올성 지방간 질환의 진단적 평가
대한내과학회지
2020 .10
-
Recent research trends and updates on nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2019 .01
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
Journal of Yeungnam Medical Science
2019 .01
-
The Immune Landscape in Nonalcoholic Steatohepatitis
Immune Network
2016 .06
-
Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology
영남의대학술지
2019 .01
-
State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
Endocrinology and Metabolism
2022 .02
-
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2020 .01
-
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2023 .02
-
Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis
Clinical and Molecular Hepatology
2021 .01
-
Recent advances in nonalcoholic fatty liver disease metabolomics
Clinical and Molecular Hepatology
2021 .10
-
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Clinical and Molecular Hepatology
2023 .02
-
Liver transplantation for non-alcoholic fatty liver disease: indications and post-transplant management
Clinical and Molecular Hepatology
2023 .02
-
Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients
전남의대학술지
2024 .01
-
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Diabetes and Metabolism Journal
2020 .01
-
Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
Endocrinology and Metabolism
2020 .01
-
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Diabetes and Metabolism Journal
2019 .01
-
Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2015 .01
-
Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Clinical and Molecular Hepatology
2023 .02
-
Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
Clinical and Molecular Hepatology
2023 .04
-
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
이 논문의 저자 정보
최근 본 자료
댓글(0)
0